2011 Advances in the Diagnosis and Treatment of the Rheumatic Diseases

Accreditation Statement

The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement

The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 9.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Release Date: April 4, 2012
Expiration Date: April 4, 2015

Description

Now in its seventh year, this two-day symposium has been planned for the providers of care to patients with rheumatic diseases. Given the wide variety of rheumatologic disorders, and an ever increasing number of diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of these conditions, novel state-of-the-art diagnostic tools, and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.

Target Audience

This activity is intended for rheumatologists, internists, gerontologists, orthopedic surgeons, nurses, nurse practitioners, and other allied health professionals.

Objectives

After attending this activity, the participant will demonstrate the ability to:

  • Discuss immunology and its role in auto-immune diseases and new treatments
  • Identify new diagnostic criteria for rheumatoid arthritis
  • Discuss updated American College of Rheumatology and EULAR treatment guidelines for rheumatoid arthritis
  • Discuss new and emerging issues in the management of osteoporosis
  • Identify major issues related to the management of patients with lupus and anti-phospholipid syndrome
  • Recognize which imaging sequences or views, (MRI, ultrasound, radiographs, etc.) reveal the most information when used in the diagnosis of rheumatic diseases
  • Identify new information and treatments in the management of osteoarthritis
  • Recognize new advances in elbow, hand and wrist conditions common in inflammatory arthritis
  • Discuss new treatment strategies in Gout
  • Discuss patient education and health literacy
  • Identify new and emerging treatments through complimentary medicine for the rheumatic diseases
  • Recognize available resources for people unable to access appropriate care
  • Identify the importance of practice guidelines and their related protocols
  • Identify and perform new treatment options for patients with psoriatic arthritis and ankylosing spondylitis

Notice About Off-Label Use Presentations

The Johns Hopkins University School of Medicine/ Sixth Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases (EM) may include presentations on drugs or devices, or use of drugs or devices, which have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.

Copyright Information

All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.

Instructions to obtain a CME Certificate for this activity

To obtain CME Credits for this activity, you must register online at http://www.hopkinscme.edu/CourseDetail.aspx/80029414  After you have registered and paid the $45 registration fee, please follow the steps given on the website to complete your post-test.

A Certificate of Credits will be given upon passing the post-test with a score of at least 70% or better.  Registrations will not be accepted after April 4, 2015.

Policy on Speaker and Provider Disclosure

It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s).  The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.

Full Disclosure Policy Affecting CME Activities

As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation.  The presenting faculty reported the following:

SPEAKERS NAME AND LECTURE TITLES RELATIONSHIPS
 John Carrino, MD, MPH : Musculoskeletal Radiology-Pearls for the Rheumatologist Grants/Research: Carestream, Siemens and Toshiba; Consultant:Quality Medical Metrics
Maxime Dougados, MD : Incorporating the New Rheumatoid Arthritis Criteria and Guidelines into Practice Consultant/Advisor/Grant: Abbott,  Bristol-Myers Squibb, Pfizer, Roche and UCB
Janet Maynard, MD : Gone with the Gout: An Epic Tale of Crystal Induced Arthritis Grants/Research: Takeda
Kenneth Saag, MD : Advances in Osteoporosis 2011: Opportunities and Challenges Consultant: Amgen, Eli Lilly, Merck and Novartis; Grants/Research:Amgen, Eli Lilly, Merck and Novartis
Thomas Schnitzer, MD : Update on Pain Mechanisms of OA: Implications for Therapy Grants/Research: Eli Lilly and Pfizer

All other speakers have indicated that they have not received financial support for consultation, research or evaluation or have a financial interest relevant to their presentation.

Note:  Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

PLANNERS NAME RELATIONSHIP(S)
Clifton Bingham, III, MD
  •  Consultant: Allos, Celegene, Centocor, Flexion, Genentech/Roche, Millenium, Pfizer and UCB
  • Grant Support to the Johns Hopkins Arthritis Center website: Abbott, Amgen, Bristol-Myers Squibb, Centocor and Genentech/Roche

No other planners have indicated that they have any financial interests or relationships with a commercial entity.

Note:  Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).

OFF-LABEL PRODUCT DISCUSSION

The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:

NAME AND LECTURE TITLES PRODUCT
Francesco Boin, MD : Management of Raynaud’s Diseases and Digital Ulcers in Scleroderma Sildenafil, epoprostenol, botox
Case Discussion Rituximab, cyclophosphamide and mofetil mycophenolate 
Sonye Danoff, MD : Practical Pulmonology for the Rheumatologist Prednisone, Azathioprine, Mycophenolate, Cyclophosphamide and LVLG 
James Dunn, MD :Ophthalmology in Rheumatic Disease Use of immunosuppressive drugs for uveitis and scleritis 
Derek Fine, MD : Lupus Nephritis All drugs used in the treatment of LN are off-label
Janet Maynard, MD : Gone with the Gout: An Epic Tale of Crystal Induced Arthritis Kineret, Colchicine, Rilonacept and Canakinumab

 All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.

Program

Updated: July 9, 2012

Arthritis Center

About Arthritis Center

Founded in 1998, the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.